Influence of PLGA End Groups on the Release Profile of Dexamethasone from Ocular Implants

Isha Saraf, Varun Kushwah*, Carolina Alva, Ioannis Koutsamanis, Johannes Rattenberger, Hartmuth Schroettner, Claudia Mayrhofer, Dattatray Modhave, Michael Braun, Bernd Werner, Klaus Zangger, Amrit Paudel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The present study deals with the development of dexamethasone (DM)-loaded implants using ester end-capped Resomer RG 502 poly(lactic acid-co-glycolic acid) (PLGA) (502), acid end-capped Resomer RG 502H PLGA (502H), and a 502H:502 mixture (3:1) via hot melt extrusion (HME). The prepared intravitreal implants (20 and 40% DM loaded in each PLGA) were thoroughly investigated to determine the effect of different end-capped PLGA and drug loading on the long-term release profile of DM. The implants were characterized for solid-state active pharmaceutical ingredient (APIs) using DSC and SWAXS, water uptake during stability study, the crystal size of API in the implant matrix using hot-stage polarized light microscopy, and in vitro release profile. The kinetics of PLGA release was thoroughly investigated using quantitative 1H NMR spectroscopy. The polymorph of DM crystal was found to remain unchanged after the extrusion and stability study. However, around 3 times reduction in API particle size was observed after the HME process. The morphology and content uniformity of the RT-stored samples were found to be comparable to the initial implant samples. Interestingly, the samples (mainly 502H) stored at 40 °C and 75% RH for 30 d demonstrated marked deformation and a change in content uniformity. The rate of DM release was higher in the case of 502H samples with a higher drug loading (40% w/w). Furthermore, a simple digital in vitro DM release profile derived for the formulation containing a 3:1 ratio of 502H and 502 was comparable with the experimental release profile of the respective polymer mixture formulation. The temporal development of pores and/or voids in the course of drug dissolution, evaluated using μCT, was found to be a precursor for the PLGA release. Overall, the release profile of DM was found to be dependent on the PLGA type (independent of subtle changes in the formulation mass and diameter). However, the extent of release was found to be dependent on DM loading. Thus, the present investigation led to a thorough understanding of the physicochemical properties of different end-capped PLGAs and the underlying formulation microstructure on the release profile of a crystalline water-insoluble drug, DM, from the PLGA-based implant.

Original languageEnglish
Pages (from-to)1307-1322
Number of pages16
JournalMolecular Pharmaceutics
Volume20
Issue number2
DOIs
Publication statusPublished - 2023

Keywords

  • dexamethasone
  • digital release profile
  • hot melt extrusion
  • in vitro long-term release
  • intravitreal implant
  • NMR
  • PLGA
  • PLGA end capping

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Molecular Medicine

Fields of Expertise

  • Human- & Biotechnology

Treatment code (Nähere Zuordnung)

  • Basic - Fundamental (Grundlagenforschung)

Fingerprint

Dive into the research topics of 'Influence of PLGA End Groups on the Release Profile of Dexamethasone from Ocular Implants'. Together they form a unique fingerprint.

Cite this